Abstract
Introduction Growing evidence supports combining social, behavioral and biomedical strategies to strengthen the HIV care continuum. However, combination interventions can be resource-intensive and challenging to scale up. Research is needed to identify intervention components and delivery models that maximize uptake, engagement and effectiveness. In New York City (NYC), a multi-component Ryan White-funded medical case management intervention called the Care Coordination Program (CCP) was launched at 28 agencies in 2009 to address barriers to care and treatment. Effectiveness estimates based on >7,000 clients enrolled by April 2013 and their controls indicated modest CCP benefits over ‘usual care’ for short- and long-term viral suppression, with substantial room for improvement.
Methods and analysis Integrating evaluation findings and CCP service-provider and community-stakeholder input on modifications, the NYC Health Department packaged a Care Coordination Redesign (CCR) in a 2017 request for proposals. Following competitive re-solicitation, 17 of the original CCP-implementing agencies secured contracts. These agencies were randomized within matched pairs to immediate or delayed CCR implementation. Data from three nine-month periods (pre-implementation, partial implementation and full implementation) will be examined to compare CCR versus CCP effects on timely viral suppression (TVS, within four months of enrollment) among individuals with unsuppressed HIV viral load newly enrolling in the CCR/CCP. Based on estimated enrollment (n=824) and the pre-implementation outcome probability (TVS=0.45), the detectable effect size with 80% power is an odds ratio of 2.90 (relative risk: 1.56).
Ethics and dissemination This study was approved by the NYC Department of Health and Mental Hygiene Institutional Review Board (IRB, Protocol 18-009) and the City University of New York Integrated IRB (Protocol 018-0057) with a waiver of informed consent. Findings will be disseminated via publications, conferences, stakeholder meetings, and Advisory Board meetings with implementing agency representatives.
Trial registration Registered with ClinicalTrials.gov under identifier: NCT03628287, Version 2, 25 September 2019; pre-results.
Strengths and limitations of this study
The PROMISE trial, conducted in real-world service settings, leverages secondary analyses of programmatic and surveillance data to assess the effectiveness of a revised (CCR) versus original HIV care coordination program to improve viral suppression.
To meet stakeholder expectations for rapid completion of the CCR rollout, the study applies a stepped-wedge design with a nine-month gap between implementation phases, prompting use of a short-term (four-month) outcome and a brief (five-month) lead-in time for enrollment accumulation.
Randomization is performed at the agency level to minimize crossover between the intervention conditions, since service providers would otherwise struggle logistically and ethically with simultaneously delivering the two different intervention models to different sets of clients, especially given common challenges related to reaching agreement on clinical equipoise.1–3
The use of agency matching, when followed by randomization within matched pairs, offers advantages akin to those of stratified random assignment: increasing statistical power in a situation where the number of units of randomization is small, by maximizing equivalency between the intervention and control groups on key observable variables, thus helping to isolate the effects of the intervention.3
In addition, nuisance parameters are removed through the conditional analytic approach, which accounts and allows for the unavoidably imperfect matching of agencies and arbitrary variation of period effects across agency pairs.4
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Registered with ClinicalTrials.gov under identifier: NCT03628287, Version 2, 25 September 2019; pre-results.
Funding Statement
This work was supported by the National Institutes of Health (NIH), grant number R01 MH117793 and by a Health Resources and Services Administration (HRSA) Ryan White Part A grant (HA89HA00015) covering HIV program delivery, quality improvement and administration (Project Officer Sera Morgan, SMorgan{at}hrsa.gov). The NIH and HRSA are not involved in the study design, conduct or products, nor in the decision to submit this work for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(bl6{at}columbia.edu), (McKaylee.Robertson{at}sph.cuny.edu), (kpenrose04{at}yahoo.com), (jcarmona{at}health.nyc.gov), (gharriman{at}health.nyc.gov), (sbraunstein{at}health.nyc.gov), (Denis.Nash{at}sph.cuny.edu)
Data Availability
The full IRB protocol and statistical code will be made available by the investigators upon request. Due to legal restrictions (New York Public Health Law Article 21, Title III) and the confidential nature of HIV surveillance data, the study team cannot release a de-identified individual-level public-use dataset. NYC Health Department staff retain sole custody of the merged study datasets and are available to assist external researchers with any inquiries. Requests can be sent via email to hivreport{at}health.nyc.gov.
